National HIV CurriculumLogo
Common TitleHPTN 083
Official Title A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Men Who Have Sex With Men and Other Populations
Purpose / DescriptionPhase IIb/III
Phase Phase III
ClinicalTrials.gov NCT02720094
Treatments
Cabotegravir

Cabotegravir

Tradename:ApretudeOther Names:CAB-LA, Injectable cabotegravirClass:Long-Acting Injectable Regimens
Categories PREP
Funding
IndustryViiV Healthcare
Non-IndustryNational Institute of Allergy and Infectious Diseases (NIAID)
References
  • Landovitz RJ, Donnell D, Clement ME, et al. N Engl J Med. 2021;385:595-608.
    [PubMed Abstract]

Share by e-mail

The Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,175,136. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.